Adjuvant 131I-metuximab in hepatocellular carcinoma: a new option for an old drug?
Mené en Chine sur 156 patients atteints d'un carcinome hépatocellulaire et ayant subi une hépatectomie (âge : de 18 à 75 ans ; durée médiane de suivi : 55,9 mois), cet essai multicentrique de phase II évalue l'efficacité, du point de vue de la survie sans récidive à 5 ans, et la toxicité d'un traitement adjuvant par injection transartérielle de métuximab marqué à l'iode 131, un anticorps monoclonal dirigé contre l'antigène CD147 des cellules hépatiques cancéreuses
Liver cancer is the fifth most common cancer and the second most common cause of cancer-related death worldwide. The incidence of liver cancer varies geographically and is highest in Africa and Asia. These regions also have a high prevalence of hepatitis B virus (HBV) and hepatitis C virus infections, which are the most important causes of chronic liver diseases. Local ablation, liver resection, and orthotopic liver transplantation are considered potentially curative treatment modalities for patients with hepatocellular carcinoma (HCC). Despite these curative-intent approaches, tumour recurrence occurs in 50–70% of patients within 5 years of surgery, either as early intrahepatic metastases or as new HCC foci that develop in the liver remnants. No adjuvant treatment has shown convincing efficacy in HCC thus far. Therefore, considering that a high number of patients develop recurrence, there is an evident unmet clinical need.
The Lancet Gastroenterology & Hepatology , commentaire, 2019